AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%

ANAPTYSBIO, INC

2026-Q1 EPS reported -$1.84 revenue$25,556,000

Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.
Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.
Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.
FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANAPTYSBIO, INC reported first quarter ended March 31, 2026 results: revenue Collaboration revenue was $25.6 million for the three months ended March 31, 2026, net income Net loss was $52.9 million for the three months ended March 31, 2026, or a net loss per share of $1.84, EPS net loss per share of $1.84.

Period: first quarter ended March 31, 2026
Revenue: Collaboration revenue was $25.6 million for the three months ended March 31, 2026
Net income: Net loss was $52.9 million for the three months ended March 31, 2026, or a net loss per share of $1.84
EPS: net loss per share of $1.84
Result: reported results

Exact text from the filing

On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-219500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.